Cabotegravir (Apretude) vs VH4524184

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HIV

Shared mechanism: HIV integrase · full HIV pipeline

Cabotegravir (Apretude)

Marketed by GlaxoSmithKline

Approved in HIVsmall molecule
Reliable signal

NCT02720094 · Phase 2/3 · completed

The trial randomized 4,570 participants to cabotegravir or active-controlled TDF/FTC treatment and used quadruple blinding of participants, clinicians, investigators, and outcome assessors. Its hard clinical primary efficacy endpoint—documented incident HIV infection—was met, with 13 versus 39 infections and a hazard ratio of 0.340 (95% CI 0.18–0.62; p=0.0005).

Next expected readout: August 2028 · NCT06474364 (registry estimate)

Reported efficacy

Number of Participants With Documented Incident HIV Infections During Steps 1 and 2 (HIV tests at enrollment, weeks 2, 4, 5, every injection visit (every 8 weeks) and every safety visit (2 weeks after each injection visit). Analyzed through week 153 or the date of DSMB decision to unblind all participants, whichever is earliest.); Number of Participants Experiencing Grade 2 or Higher Clinical and Laboratory Adverse Events (Treatment emergent AE* measured with onset date through participant's last study visit, or the date of DSMB decision to unblind all participants, whichever is earliest. Assessed at each visit (injections visits q 8 weeks and safety visits q 8 weeks).): Number of Participants With Documented Incident HIV Infections During Steps 1 and 2 (HIV tests at enrollment, weeks 2, 4, 5, every injection visit (every 8 weeks) and every safety visit (2 weeks after each injection visit). Analyzed through week 153 or the date of DSMB decision to unblind all participants, whichever is earliest.): Cabotegravir 13/2280 vs TDF/FTC 39/2281 (met)

Result source: NCT02720094

VH4524184

Developed by ViiV Healthcare

Phase 2 in HIVsmall molecule
Partial signal

NCT06214052 · Phase 2 · completed

The study was randomized and double-blind with matching placebo, but it was very small, with 6, 6, and 7 participants receiving VH4524184 doses and only 3 receiving placebo. Its primary endpoint was a surrogate measure of plasma HIV-1 RNA change, and although the reported mean changes favored the medium and high doses, statistical significance was not reported.

Next expected readout: October 2027 · NCT07202546 (registry estimate)

Reported efficacy

Monotherapy: Maximum Change From Baseline in Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) (At Day 10): Monotherapy: Maximum Change From Baseline in Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) (At Day 10): VH4524184 Dose 1 -1.17 Copies per milliliter (copies/mL) (Standard Deviation 0.46) | VH4524184 Dose 2 -2.15 Copies per milliliter (copies/mL) (Standard Deviation 0.254) | VH4524184 Dose 3 -2.31 Copies per milliliter (copies/mL) (Standard Deviation 0.463) vs Placebo -0.28 Copies per milliliter (copies/mL) (Standard Deviation 0.37) (unclear)

Result source: NCT06214052

Results for HIV

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointCabotegravir (Apretude)VH4524184
HIV-1 RNA below 50 copies/mL (week 48)—Trial running · NCT06133686—Not reported
HIV-1 RNA 50 copies/mL or more (week 48)—Trial running · NCT06133686—Not reported
CD4 count, change (week 48)—Trial running · NCT06133686—Not reported

HIV-1 RNA below 50 copies/mL (week 48)

Cabotegravir (Apretude)
—Trial running · NCT06133686
VH4524184
—Not reported

HIV-1 RNA 50 copies/mL or more (week 48)

Cabotegravir (Apretude)
—Trial running · NCT06133686
VH4524184
—Not reported

CD4 count, change (week 48)

Cabotegravir (Apretude)
—Trial running · NCT06133686
VH4524184
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Cabotegravir (Apretude)
Number of Participants With Documented Incident HIV Infections During Steps 1 and 2 (HIV tests at enrollment, weeks 2, 4, 5, every injection visit (every 8 weeks) and every safety visit (2 weeks after each injection visit). Analyzed through week 153 or the date of DSMB decision to unblind all participants, whichever is earliest.): Cabotegravir 13/2280 vs TDF/FTC 39/2281 NCT02720094 · Phase 2/3 · design grade: strong · reviewed ClinicalTrials.gov result

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Cabotegravir (Apretude): 0 of 4 rows · VH4524184: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricVH4524184
Dropout rate
0%Dose 1
NCT06214052 · Phase 2 · combination · HIV · phase 2
show 8 more results
—Dose 1
NCT06214052 · Phase 2 · combination · HIV · phase 2
—Dose 1
NCT06214052 · Phase 2 · combination · HIV · phase 2
0%Dose 2
NCT06214052 · Phase 2 · combination · HIV · phase 2
—Dose 2
NCT06214052 · Phase 2 · combination · HIV · phase 2
—Dose 2
NCT06214052 · Phase 2 · combination · HIV · phase 2
0%Dose 3
NCT06214052 · Phase 2 · combination · HIV · phase 2
—Dose 3
NCT06214052 · Phase 2 · combination · HIV · phase 2
—Dose 3
NCT06214052 · Phase 2 · combination · HIV · phase 2
Discontinued due to AEs
—Dose 1
NCT06214052 · Phase 2 · combination · HIV · phase 2
show 8 more results
—Dose 1
NCT06214052 · Phase 2 · combination · HIV · phase 2
—Dose 1
NCT06214052 · Phase 2 · combination · HIV · phase 2
—Dose 2
NCT06214052 · Phase 2 · combination · HIV · phase 2
—Dose 2
NCT06214052 · Phase 2 · combination · HIV · phase 2
—Dose 2
NCT06214052 · Phase 2 · combination · HIV · phase 2
—Dose 3
NCT06214052 · Phase 2 · combination · HIV · phase 2
—Dose 3
NCT06214052 · Phase 2 · combination · HIV · phase 2
—Dose 3
NCT06214052 · Phase 2 · combination · HIV · phase 2
Serious AEs
—Dose 1
NCT06214052 · Phase 2 · combination · HIV · phase 2
show 8 more results
0%Dose 1
NCT06214052 · Phase 2 · combination · HIV · phase 2
0%Dose 1
NCT06214052 · Phase 2 · combination · HIV · phase 2
—Dose 2
NCT06214052 · Phase 2 · combination · HIV · phase 2
0%Dose 2
NCT06214052 · Phase 2 · combination · HIV · phase 2
0%Dose 2
NCT06214052 · Phase 2 · combination · HIV · phase 2
—Dose 3
NCT06214052 · Phase 2 · combination · HIV · phase 2
0%Dose 3
NCT06214052 · Phase 2 · combination · HIV · phase 2
0%Dose 3
NCT06214052 · Phase 2 · combination · HIV · phase 2
Most frequent reported AEs
Dose 1
abdominal distension 16.7% (placebo 0%)
acute sinusitis 16.7% (placebo 0%)
dermatitis 16.7% (placebo 0%)
NCT06214052 · Phase 2 · combination · HIV · phase 2
show 5 more results
Dose 1
dermatitis 16.7% (placebo 0%)
diarrhoea 16.7% (placebo 33.3%)
abdominal distension 0% (placebo 0%)
NCT06214052 · Phase 2 · combination · HIV · phase 2
Dose 2
alanine aminotransferase increased 16.7% (placebo 0%)
gastroenteritis 16.7% (placebo 33.3%)
hypertension 16.7% (placebo 0%)
NCT06214052 · Phase 2 · combination · HIV · phase 2
Dose 2
amylase increased 16.7% (placebo 0%)
fatigue 16.7% (placebo 0%)
lipase increased 16.7% (placebo 0%)
NCT06214052 · Phase 2 · combination · HIV · phase 2
Dose 3
abdominal distension 14.3% (placebo 0%)
diarrhoea 14.3% (placebo 33.3%)
dyspepsia 14.3% (placebo 0%)
NCT06214052 · Phase 2 · combination · HIV · phase 2
Dose 3
dizziness 14.3% (placebo 0%)
headache 14.3% (placebo 66.7%)
influenza like illness 14.3% (placebo 0%)
NCT06214052 · Phase 2 · combination · HIV · phase 2

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

VH4524184

HIV-1 RNA -1.17 vs -0.28 placebo copies/mL @ 1.43wkDose 1
absolute change · copies/mL
NCT06214052 · Phase 2 · combination · HIV · phase 2
show 2 more results
-2.15 vs -0.28 placebo copies/mL @ 1.43wkDose 2
NCT06214052 · Phase 2 · combination · HIV · phase 2
-2.31 vs -0.28 placebo copies/mL @ 1.43wkDose 3
NCT06214052 · Phase 2 · combination · HIV · phase 2
CD4+ 131.333 vs 63.667 placebo cells/uL @ 1.43wkDose 1
absolute change · cells/uL
NCT06214052 · Phase 2 · combination · HIV · phase 2
show 2 more results
68.667 vs 63.667 placebo cells/uL @ 1.43wkDose 2
NCT06214052 · Phase 2 · combination · HIV · phase 2
47 vs 63.667 placebo cells/uL @ 1.43wkDose 3
NCT06214052 · Phase 2 · combination · HIV · phase 2

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Cabotegravir (Apretude)'s landscape · VH4524184's landscape